Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $17.4 million.

  • Ptc Therapeutics' Other Accumulated Expenses rose 1516.84% to $17.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.4 million, marking a year-over-year increase of 1516.84%. This contributed to the annual value of $20.6 million for FY2024, which is 9297.36% up from last year.
  • Latest data reveals that Ptc Therapeutics reported Other Accumulated Expenses of $17.4 million as of Q3 2025, which was up 1516.84% from $28.3 million recorded in Q2 2025.
  • Ptc Therapeutics' Other Accumulated Expenses' 5-year high stood at $28.3 million during Q2 2025, with a 5-year trough of $6.8 million in Q2 2021.
  • Over the past 5 years, Ptc Therapeutics' median Other Accumulated Expenses value was $10.7 million (recorded in 2023), while the average stood at $12.6 million.
  • In the last 5 years, Ptc Therapeutics' Other Accumulated Expenses tumbled by 1144.85% in 2023 and then soared by 13597.63% in 2025.
  • Ptc Therapeutics' Other Accumulated Expenses (Quarter) stood at $12.6 million in 2021, then fell by 4.63% to $12.1 million in 2022, then fell by 11.45% to $10.7 million in 2023, then surged by 92.97% to $20.6 million in 2024, then decreased by 15.66% to $17.4 million in 2025.
  • Its Other Accumulated Expenses was $17.4 million in Q3 2025, compared to $28.3 million in Q2 2025 and $18.9 million in Q1 2025.